The DOI matches its Crossref record; 325 of the 325 references it cites were found in a registry or an index.
The Role of Oxidative Stress in Parkinson’s Disease
Open accessAbstract
Parkinson’s disease (PD) is caused by progressive neurodegeneration of dopaminergic (DAergic) neurons with abnormal accumulation of α-synuclein in substantia nigra (SN). Studies have suggested the potential involvement of dopamine, iron, calcium, mitochondria and neuroinflammation in contributing to overwhelmed oxidative stress and neurodegeneration in PD. Function studies on PD-causative mutations of SNCA, PRKN, PINK1, DJ-1, LRRK2, FBXO7 and ATP13A2 further indicate the role of oxidative stress in the pathogenesis of PD. Therefore, it is reasonable that molecules involved in oxidative stress, such as DJ-1, coenzyme Q10, uric acid, 8-hydroxy-2’-deoxyguanosin, homocysteine, retinoic acid/carotenes, vitamin E, glutathione peroxidase, superoxide dismutase, xanthine oxidase and products of lipid peroxidation, could be candidate biomarkers for PD. Applications of antioxidants to modulate oxidative stress could be a strategy in treating PD. Although a number of antioxidants, such as creatine, vitamin E, coenzyme Q10, pioglitazone, melatonin and desferrioxamine, have been tested in clinical trials, none of them have demonstrated conclusive evidence to ameliorate the neurodegeneration in PD patients. Difficulties in clinical studies may be caused by the long-standing progression of neurodegeneration, lack of biomarkers for premotor stage of PD and inadequate drug delivery across blood–brain barrier. Solutions for these challenges will be warranted for future studies with novel antioxidative treatment in PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Ighodaro, O. M., & Akinloye, O. A. (2018) · Alexandria Journal of Medicine · doi:10.1016/j.ajme.2017.09.001 · Cited by 3,939
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin
Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D.-F., Gautier, C. A., Shen, J., Cookson, M. R., & Youle, R. J. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000298 · Cited by 2,944
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis
Su, L.-J., Zhang, J.-H., Gomez, H., Murugan, R., Hong, X., Xu, D., Jiang, F., & Peng, Z.-Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5080843 · Cited by 2,166
Microglia and macrophages in brain homeostasis and disease
Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
8-hydroxy-2′ -deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and Carcinogenesis
VALAVANIDIS, A., VLACHOGIANNI, T., & FIOTAKIS, C. (2009) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590500902885684 · Cited by 1,978
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Miean, K. H., & Mohamed, S. (2001) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf000892m · Cited by 1,371
Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Lotharius, J., & Brundin, P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn983 · Cited by 1,283
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
The genetic architecture of Parkinson's disease
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30287-x · Cited by 1,114
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., & Anandatheerthavarada, H. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710012200 · Cited by 1,080
Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 1,057
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Dagda, R. K., Cherra, S. J., Kulich, S. M., Tandon, A., Park, D., & Chu, C. T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808515200 · Cited by 954
Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight
Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi, M. A., & Ganie, S. A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.025 · Cited by 928
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang-James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 857
Kim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818
Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J., Pugh, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.642 · Cited by 784
Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis
Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., & Patel, B. K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00025 · Cited by 774
Keeney, P. M., Xie, J., Capaldi, R. A., & Bennett, J. P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0984-06.2006 · Cited by 747
LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress
Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R. E., Langston, W., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.01.013 · Cited by 745
Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin
Ziviani, E., Tao, R. N., & Whitworth, A. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913485107 · Cited by 735
Dopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701
Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress
Gautier, C. A., Kitada, T., & Shen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802076105 · Cited by 698
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Gureev, A. P., Shaforostova, E. A., & Popov, V. N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00435 · Cited by 643
PGC-1 α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism
Rius-Pérez, S., Torres-Cuevas, I., Millán, I., Ortega, Á. L., & Pérez, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1452696 · Cited by 642
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
Calcium Signaling and Reactive Oxygen Species in Mitochondria
Bertero, E., & Maack, C. (2018) · Circulation Research · doi:10.1161/circresaha.118.310082 · Cited by 617
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Cheung, Y.-T., Lau, W. K.-W., Yu, M.-S., Lai, C. S.-W., Yeung, S.-C., So, K.-F., & Chang, R. C.-C. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2008.11.001 · Cited by 576
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., & Nagatsu, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12706-3 · Cited by 545
Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., Marsden, C. D., & The Royal Kings And Queens Parkinson's Disease Research Group (1992) · Annals of Neurology · doi:10.1002/ana.410320714 · Cited by 544
Physiological functions and pathogenic potential of uric acid: A review
El Ridi, R., & Tallima, H. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.03.003 · Cited by 542
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Park, J.-S., Davis, R. L., & Sue, C. M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0829-3 · Cited by 516
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508
Oxidative stress in Huntington’s disease
Browne, S. E., Ferrante, R. J., & Beal, M. F. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00216.x · Cited by 508
Ge, P., Dawson, V. L., & Dawson, T. M. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00367-7 · Cited by 496
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474
Oxidative Stress and Its Significant Roles in Neurodegenerative Diseases and Cancer
Thanan, R., Oikawa, S., Hiraku, Y., Ohnishi, S., Ma, N., Pinlaor, S., Yongvanit, P., Kawanishi, S., & Murata, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010193 · Cited by 455
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Chinta, S. J., Mallajosyula, J. K., Rane, A., & Andersen, J. K. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.061 · Cited by 449
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Morais, V. A., Verstreken, P., Roethig, A., Smet, J., Snellinx, A., Vanbrabant, M., Haddad, D., Frezza, C., Mandemakers, W., Vogt‐Weisenhorn, D., et al. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900006 · Cited by 434
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1
Wang, X., Yan, M. H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S. G., Perry, G., Casadesus, G., & Zhu, X. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds003 · Cited by 424
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418
Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu, M., Debré, P., Agid, Y., Dugas, B., & Hirsch, E. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03440.1999 · Cited by 408
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 408
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Herrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392
Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats
Jin, F., Wu, Q., Lu, Y.-F., Gong, Q.-H., & Shi, J.-S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.005 · Cited by 384
Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.-H., Doudnikoff, E., Vital, A., Vila, M., Klein, C., & Bezard, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112368109 · Cited by 379
Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity
Matthews, R. T., Ferrante, R. J., Klivenyi, P., Yang, L., Klein, A. M., Mueller, G., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 373
Loss of Parkin or PINK1 Function Increases Drp1-dependent Mitochondrial Fragmentation
Lutz, A. K., Exner, N., Fett, M. E., Schlehe, J. S., Kloos, K., Lämmermann, K., Brunner, B., Kurz-Drexler, A., Vogel, F., Reichert, A. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.035774 · Cited by 373
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., & Singleton, A. B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104782 · Cited by 370
Ozturk, B., Argin, S., Ozilgen, M., & McClements, D. J. (2015) · Food Chemistry · doi:10.1016/j.foodchem.2015.05.005 · Cited by 360
Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase
Hastings, T. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020919.x · Cited by 359
Pathological roles of α-synuclein in neurological disorders
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., & Stefanis, L. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70213-7 · Cited by 357
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio, A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.247 · Cited by 354
The role of Nrf2 signaling in counteracting neurodegenerative diseases
Dinkova‐Kostova, A. T., Kostov, R. V., & Kazantsev, A. G. (2018) · The FEBS Journal · doi:10.1111/febs.14379 · Cited by 342
C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction
Lautenschläger, J., Stephens, A. D., Fusco, G., Ströhl, F., Curry, N., Zacharopoulou, M., Michel, C. H., Laine, R., Nespovitaya, N., Fantham, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03111-4 · Cited by 334
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death
Junn, E., Taniguchi, H., Jeong, B. S., Zhao, X., Ichijo, H., & Mouradian, M. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409635102 · Cited by 321
Braak, H., Sastre, M., Bohl, J. R. E., de Vos, R. A. I., & Del Tredici, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0193-x · Cited by 321
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. S. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002455 · Cited by 316
Vitamin E: Regulatory Redox Interactions
Miyazawa, T., Burdeos, G. C., Itaya, M., Nakagawa, K., & Miyazawa, T. (2019) · IUBMB Life · doi:10.1002/iub.2008 · Cited by 315
Kausar, S., Wang, F., & Cui, H. (2018) · Cells · doi:10.3390/cells7120274 · Cited by 311
Tryptophan metabolism and oxidative stress in patients with Huntington's disease
Stoy, N., Mackay, G. M., Forrest, C. M., Christofides, J., Egerton, M., Stone, T. W., & Darlington, L. G. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03070.x · Cited by 310
Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
Schwarzschild, M. A. (2008) · Archives of Neurology · doi:10.1001/archneur.2008.65.6.nct70003 · Cited by 310
Dietary lipids and antioxidants in Parkinson's disease: A population‐based, case‐control study
Logroscino, G., Marder, K., Cote, L., Tang, M., Shea, S., & Mayeux, R. (1996) · Annals of Neurology · doi:10.1002/ana.410390113 · Cited by 305
McNaught, K. S. P., Mytilineou, C., JnoBaptiste, R., Yabut, J., Shashidharan, P., Jenner, P., & Olanow, C. W. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00821.x · Cited by 304
Byers, B., Cord, B., Nguyen, H. N., Schüle, B., Fenno, L., Lee, P. C., Deisseroth, K., Langston, J. W., Pera, R. R., & Palmer, T. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026159 · Cited by 302
Mudò, G., Mäkelä, J., Liberto, V. D., Tselykh, T. V., Olivieri, M., Piepponen, P., Eriksson, O., Mälkiä, A., Bonomo, A., Kairisalo, M., et al. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0850-z · Cited by 301
Ben‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299
Tarocco, A., Caroccia, N., Morciano, G., Wieckowski, M. R., Ancora, G., Garani, G., & Pinton, P. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1556-7 · Cited by 299
Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E., & Masliah, E. (2004) · Experimental Neurology · doi:10.1016/s0014-4886(03)00342-x · Cited by 295
Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy
Qian, L., Flood, P. M., & Hong, J.-S. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0428-1 · Cited by 287
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
Mallajosyula, J. K., Kaur, D., Chinta, S. J., Rajagopalan, S., Rane, A., Nicholls, D. G., Di Monte, D. A., Macarthur, H., & Andersen, J. K. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001616 · Cited by 286
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2
Pankratz, N., Beecham, G. W., DeStefano, A. L., Dawson, T. M., Doheny, K. F., Factor, S. A., Hamza, T. H., Hung, A. Y., Hyman, B. T., Ivinson, A. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22687 · Cited by 285
Khan, M. M., Ahmad, A., Ishrat, T., Khan, M. B., Hoda, M. N., Khuwaja, G., Raza, S. S., Khan, A., Javed, H., Vaibhav, K., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.031 · Cited by 279
Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats
Melchiorri, D. (1995) · Life Sciences · doi:10.1016/0024-3205(94)00417-q · Cited by 275
Lastres-Becker, I., García-Yagüe, A. J., Scannevin, R. H., Casarejos, M. J., Kügler, S., Rábano, A., & Cuadrado, A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6549 · Cited by 274
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Medeiros, C. A. M., Carvalhedo de Bruin, P. F., Lopes, L. A., Magalhães, M. C., de Lourdes Seabra, M., & Sales de Bruin, V. M. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0390-x · Cited by 269
Lastres-Becker, I., Ulusoy, A., Innamorato, N. G., Sahin, G., Rábano, A., Kirik, D., & Cuadrado, A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds143 · Cited by 263
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Ilijic, E., Guzman, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 259
Oxidative damage in Parkinson disease: Measurement using accurate biomarkers
Seet, R. C. S., Lee, C.-Y. J., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chong, W.-L., Looi, W.-F., Huang, S.-H., Wang, H., Chan, Y.-H., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.026 · Cited by 257
Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease
Dolgacheva, L. P., Berezhnov, A. V., Fedotova, E. I., Zinchenko, V. P., & Abramov, A. Y. (2019) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-019-09798-4 · Cited by 254
Genetics of amyotrophic lateral sclerosis: A review
Mathis, S., Goizet, C., Soulages, A., Vallat, J.-M., & Masson, G. L. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.02.030 · Cited by 253
Dietary Antioxidants and Parkinson Disease: The Rotterdam Study
de Rijk, M. C. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180070015 · Cited by 250
Nrf2-mediated protection against 6-hydroxydopamine
Jakel, R. J., Townsend, J. A., Kraft, A. D., & Johnson, J. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.01.131 · Cited by 250
Oxidative Stress and the Homeodynamics of Iron Metabolism
Bresgen, N., & Eckl, P. (2015) · Biomolecules · doi:10.3390/biom5020808 · Cited by 247
Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk
Zhang, S. M., Hernán, M. A., Chen, H., Spiegelman, D., Willett, W. C., & Ascherio, A. (2002) · Neurology · doi:10.1212/01.wnl.0000028688.75881.12 · Cited by 240
Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease
Foy, C. J. (1999) · QJM · doi:10.1093/qjmed/92.1.39 · Cited by 235
Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult
Lee, M., Hyun, D., Halliwell, B., & Jenner, P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00149.x · Cited by 232
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227
(2002) · doi:10.1016/s0304-3940(02)00016-2 · Cited by 225
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease
Devic, I., Hwang, H., Edgar, J. S., Izutsu, K., Presland, R., Pan, C., Goodlett, D. R., Wang, Y., Armaly, J., Tumas, V., et al. (2011) · Brain · doi:10.1093/brain/awr015 · Cited by 222
A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease
The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 219
(E)-4-Hydroxy-2-Nonenal May be Involved in the Pathogenesis of Parkinson’s Disease
Selley, M. L. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00021-5 · Cited by 215
Dryanovski, D. I., Guzman, J. N., Xie, Z., Galteri, D. J., Volpicelli-Daley, L. A., Lee, V. M. Y., Miller, R. J., Schumacker, P. T., & Surmeier, D. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5311-12.2013 · Cited by 212
A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease
Fahn, S. (1992) · Annals of Neurology · doi:10.1002/ana.410320722 · Cited by 211
Cui, M., Tang, X., Christian, W. V., Yoon, Y., & Tieu, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066662 · Cited by 207
Kieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207
Storch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
Bender, A., Koch, W., Elstner, M., Schombacher, Y., Bender, J., Moeschl, M., Gekeler, F., Müller-Myhsok, B., Gasser, T., Tatsch, K., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000238518.34389.12 · Cited by 204
Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease
Müller, T., Büttner, T., Gholipour, A.-F., & Kuhn, W. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00185-x · Cited by 203
Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition
Kostić, D. A., Dimitrijević, D. S., Stojanović, G. S., Palić, I. R., Đorđević, A. S., & Ickovski, J. D. (2015) · Journal of Chemistry · doi:10.1155/2015/294858 · Cited by 202
Liu, G., Zhang, C., Yin, J., Li, X., Cheng, F., Li, Y., Yang, H., Uéda, K., Chan, P., & Yu, S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.056 · Cited by 201
Melatonin is protective against MPTP-induced striatal and hippocampal lesions
Acuña-Castroviejo, D., Coto-Montes, A., Monti, M. G., Ortiz, G. G., & Reiter, R. J. (1996) · Life Sciences · doi:10.1016/s0024-3205(96)00606-6 · Cited by 199
Gegg, M. E., Cooper, J. M., Schapira, A. H. V., & Taanman, J.-W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004756 · Cited by 198
The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Rui, Q., Ni, H., Li, D., Gao, R., & Chen, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180222165418 · Cited by 196
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease
Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., Akatsu, H., Yamada, T., & Hashimoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.011 · Cited by 194
DABBENI-SALA, F., DI Santo, S., FRANCESCHINI, D., D. SKAPER, S., & PIETRO GIUSTI, A. (2001) · The FASEB Journal · doi:10.1096/fj.00-0129com · Cited by 192
Apoptotic mechanisms in mutant LRRK2-mediated cell death
Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carrì, M. T., & Barone, P. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm080 · Cited by 190
Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region
Wissemann, W. T., Hill-Burns, E. M., Zabetian, C. P., Factor, S. A., Patsopoulos, N., Hoglund, B., Holcomb, C., Donahue, R. J., Thomson, G., Erlich, H., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.10.009 · Cited by 189
F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187
Hwang, Y. P., & Jeong, H. G. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.09.009 · Cited by 187
Resveratrol: A Natural Compound with Pharmacological Potential in Neurodegenerative Diseases
Rocha‐González, H. I., Ambriz‐Tututi, M., & Granados‐Soto, V. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00045.x · Cited by 186
Graves, S. M., Xie, Z., Stout, K. A., Zampese, E., Burbulla, L. F., Shih, J. C., Kondapalli, J., Patriarchi, T., Tian, L., Brichta, L., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-019-0556-3 · Cited by 183
Tamilselvam, K., Braidy, N., Manivasagam, T., Essa, M. M., Prasad, N. R., Karthikeyan, S., Thenmozhi, A. J., Selvaraju, S., & Guillemin, G. J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/102741 · Cited by 182
The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication
Siddiqui, I. J., Pervaiz, N., & Abbasi, A. A. (2016) · Scientific Reports · doi:10.1038/srep24475 · Cited by 182
Genome-wide association study confirms extant PD risk loci among the Dutch
Simón-Sánchez, J., van Hilten, J. J., van de Warrenburg, B., Post, B., Berendse, H. W., Arepalli, S., Hernandez, D. G., de Bie, R. M. A., Velseboer, D., Scheffer, H., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.254 · Cited by 181
Inden, M., Taira, T., Kitamura, Y., Yanagida, T., Tsuchiya, D., Takata, K., Yanagisawa, D., Nishimura, K., Taniguchi, T., Kiso, Y., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.004 · Cited by 180
Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage
Stichel, C. C., Zhu, X.-R., Bader, V., Linnartz, B., Schmidt, S., & Lubbert, H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm083 · Cited by 179
Lu, K.-T., Ko, M.-C., Chen, B.-Y., Huang, J.-C., Hsieh, C.-W., Lee, M.-C., Chiou, R. Y. Y., Wung, B.-S., Peng, C.-H., & Yang, Y.-L. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf8007212 · Cited by 178
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice
Blanchet, J., Longpré, F., Bureau, G., Morissette, M., DiPaolo, T., Bronchti, G., & Martinoli, M.-G. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.024 · Cited by 177
Hurley, M. J., Brandon, B., Gentleman, S. M., & Dexter, D. T. (2013) · Brain · doi:10.1093/brain/awt134 · Cited by 177
Wruck, C. J., Claussen, M., Fuhrmann, G., Römer, L., Schulz, A., Pufe, T., Waetzig, V., Peipp, M., Herdegen, T., & Götz, M. E. (2007) · Neuropsychiatric Disorders An Integrative Approach · doi:10.1007/978-3-211-73574-9_9 · Cited by 176
Sandebring, A., Thomas, K. J., Beilina, A., van der Brug, M., Cleland, M. M., Ahmad, R., Miller, D. W., Zambrano, I., Cowburn, R. F., Behbahani, H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005701 · Cited by 176
Mitochondria-targeted antioxidants as therapies.
Smith, R. A. J., & Murphy, M. P. (2011) · PubMed · Cited by 173
The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms
Park, J., Blair, N. F., & Sue, C. M. (2015) · Movement Disorders · doi:10.1002/mds.26243 · Cited by 173
Reduced intravenous glutathione in the treatment of early parkinson's disease
Sechi, G., Deledda, M. G., Bua, G., Satta, W. M., Deiana, G. A., Pes, G. M., & Rosati, G. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(96)00103-0 · Cited by 173
Yang, L., Calingasan, N. Y., Thomas, B., Chaturvedi, R. K., Kiaei, M., Wille, E. J., Liby, K. T., Williams, C., Royce, D., Risingsong, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005757 · Cited by 172
Kaur, H., Chauhan, S., & Sandhir, R. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0469-3 · Cited by 171
Pharmacokinetics of Melatonin in Man: First Pass Hepatic Metabolism
LANE, E. A., & Moss, H. B. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-6-1214 · Cited by 171
ATP13A2 regulates mitochondrial bioenergetics through macroautophagy
Gusdon, A. M., Zhu, J., Van Houten, B., & Chu, C. T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.015 · Cited by 167
Parkin and PINK1 functions in oxidative stress and neurodegeneration
Barodia, S. K., Creed, R. B., & Goldberg, M. S. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.12.004 · Cited by 167
Singhal, N. K., Srivastava, G., Patel, D. K., Jain, S. K., & Singh, M. P. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00819.x · Cited by 166
Enhanced anticancer efficacy of α-tocopheryl succinate by conjugation with polyethylene glycol
YOUK, H., LEE, E., CHOI, M., LEE, Y., CHUNG, J., KIM, S., LEE, C., & LIM, S. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.05.014 · Cited by 165
Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
Shoulson, & Parkinson Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410430309 · Cited by 165
Nagatsu, T., & Sawada, M. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_7 · Cited by 164
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverría, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 164
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease
Jenner, P. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00013.x · Cited by 163
Protective effect of melatonin in a chronic experimental model of Parkinson’s disease
Antolı́n, I., Mayo, J. C., Sainz, R. M., del Brı́o, M. D. L. A., Herrera, F., Martı́n, V., & Rodrı́guez, C. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02551-9 · Cited by 163
Li, S., & Pu, X. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1291 · Cited by 160
Park, J.-S., Koentjoro, B., Veivers, D., Mackay‐Sim, A., & Sue, C. M. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt623 · Cited by 160
Leucine‐rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin‐like protein
Niu, J., Yu, M., Wang, C., & Xu, Z. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07809.x · Cited by 159
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
Lan, J., & Jiang, D. H. (1997) · Journal of Neural Transmission · doi:10.1007/bf01277665 · Cited by 159
Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease
Irizarry, M. C., Gurol, M. E., Raju, S., Diaz-Arrastia, R. R., Locascio, J. J., Tennis, M. K., Hyman, B. T., Growdon, J. H., Greenberg, S. M., & Bottiglieri, T. (2005) · Neurology · doi:10.1212/01.wnl.0000183063.99107.5c · Cited by 158
Liu, Z., Yu, Y., Li, X., Ross, C. A., & Smith, W. W. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.01.004 · Cited by 154
Lofrumento, D., Nicolardi, G., Cianciulli, A., Nuccio, F. D., Pesa, V. L., Carofiglio, V., Dragone, T., Calvello, R., & Panaro, M. (2014) · Innate Immunity · doi:10.1177/1753425913488429 · Cited by 153
Campolo, M., Casili, G., Biundo, F., Crupi, R., Cordaro, M., Cuzzocrea, S., & Esposito, E. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6800 · Cited by 151
Elstner, M., Morris, C. M., Heim, K., Bender, A., Mehta, D., Jaros, E., Klopstock, T., Meitinger, T., Turnbull, D. M., & Prokisch, H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0828-9 · Cited by 150
The Role of Oxidative Stress in Amyotrophic Lateral Sclerosis and Parkinson’s Disease
Baillet, A. C., Chanteperdrix, V., Trocmé, C., Casez, P., Garrel, C., & Besson, G. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0212-5 · Cited by 149
Waak, J., Weber, S. S., Görner, K., Schall, C., Ichijo, H., Stehle, T., & Kahle, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806902200 · Cited by 148
Javed, H., Azimullah, S., Khair, S. B. A., Ojha, S. K., & Haque, M. E. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0293-4 · Cited by 148
Angeles, D. C., Gan, B.-H., Onstead, L., Zhao, Y., Lim, K., Dächsel, J. C., Melrose, H. L., Farrer, M. J., Wszołek, Z. K., Dickson, D. W., et al. (2011) · Human Mutation · doi:10.1002/humu.21582 · Cited by 147
Hwang, Y. P., & Jeong, H. G. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.06.045 · Cited by 146
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age
Kaur, D., Peng, J., Chinta, S. J., Rajagopalan, S., Monte, D. A. D., Cherny, R. A., & Andersen, J. K. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.04.003 · Cited by 146
Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009) · Movement Disorders · doi:10.1002/mds.22401 · Cited by 143
Sohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143
Karunakaran, S., Diwakar, L., Saeed, U., Agarwal, V., Ramakrishnan, S., Iyengar, S., & Ravindranath, V. (2007) · The FASEB Journal · doi:10.1096/fj.06-7580com · Cited by 141
Ahn, B., Rhim, H., Kim, S. Y., Sung, Y., Lee, M., Choi, J., Wolozin, B. L., Chang, J., Lee, Y. H., Kwon, T. K., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110414200 · Cited by 140
Isobe, C., Abe, T., & Terayama, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.065 · Cited by 139
Association between Parkinson's disease and the HLA‐DRB1 locus
Ahmed, I., Tamouza, R., Delord, M., Krishnamoorthy, R., Tzourio, C., Mulot, C., Nacfer, M., Lambert, J., Beaune, P. H., Laurent‐Puig, P., et al. (2012) · Movement Disorders · doi:10.1002/mds.25035 · Cited by 139
Ye, Q., Ye, L., Xu, X.-J., Huang, B., Zhang, X., Zhu, Y., & Chen, X. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-82 · Cited by 139
Chen, J., Wei, N., Lopez-Garcia, M., Ambrose, D., Lee, J., Annelin, C., & Peterson, T. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.008 · Cited by 138
Lim, J. H., Kim, K., Kim, S. W., Hwang, O., & Choi, H. J. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.03.004 · Cited by 137
Cited by
González, P., Lozano, P., Ros, G., & Solano, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119352 · Cited by 777
Role of Coenzyme Q10 in Health and Disease: An Update on the Last 10 Years (2010–2020)
Cirilli, I., Damiani, E., Dludla, P. V., Hargreaves, I., Marcheggiani, F., Millichap, L. E., Orlando, P., Silvestri, S., & Tiano, L. (2021) · Antioxidants · doi:10.3390/antiox10081325 · Cited by 115
Reflections of an aging free radical
Halliwell, B. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.10.010 · Cited by 75
Pentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210408123807 · Cited by 73
Psychotropic medication use and Parkinson's disease risk amongst older women
Beydoun, H. A., Saquib, N., Wallace, R. B., Chen, J., Coday, M., Naughton, M. J., Beydoun, M. A., Shadyab, A. H., Zonderman, A. B., & Brunner, R. L. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51614 · Cited by 12
Metadata
- Authors
- Chang, K.-H., & Chen, C.-M.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2020-07-08
- Volume
- 9
- Issue
- 7
- Pages
- 597
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W3042059273
- Cited by
- 341
- References
- 325
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.